[144] UroGen Pharma Ltd. SEC Filing

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) filing a Form 144 notifies a proposed sale of 1,520 ordinary shares through Oppenheimer with an aggregate market value of $28,697.60, scheduled approximately for 09/08/2025. The shares were acquired as RSUs on 09/07/2023 (6,666 units reported acquired at that time). The filer also reported a prior sale on 07/28/2025 of 7,522 ordinary shares generating $143,971.08 in gross proceeds. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer. The form identifies the broker as Oppenheimer and shows ~46.26 million shares outstanding for the issuer.

Positive

• Clear regulatory disclosure of the proposed sale, broker, quantities, and acquisition method (RSU), fulfilling Rule 144 requirements
• Prior sale and proceeds are reported, improving transparency about recent insider trading activity

Negative

• Insider selling activity occurred recently (7,522 shares sold on 07/28/2025) and another sale is proposed, which may prompt investor scrutiny

Insights

Securities Analyst

TL;DR: Routine insider sale filing; amounts are small relative to total outstanding shares and follow recent dispositions.

The Form 144 documents a proposed sale of 1,520 ordinary shares and discloses a recent sale of 7,522 shares, both executed or to be executed through a broker. The shares to be sold were acquired as RSUs on 09/07/2023. In isolation, these amounts represent a de minimis fraction of the issuer's ~46.26 million shares outstanding, suggesting limited direct dilution or signaling risk. The filing meets disclosure requirements and includes the customary representation regarding material nonpublic information.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure consistent with Rule 144; insider activity is transparent but warrants monitoring if sales continue.

The notice properly identifies the broker, share counts, acquisition method (RSU), and recent sale proceeds, aligning with regulatory expectations for Section 144 sales. While the filing itself raises no governance red flags, repeated insider sales over short intervals could attract investor attention; this single filing is procedural and does not, by itself, indicate material governance issues.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Oppenheimer& Co. 85 Broad St. New York NY 10004	1520	28697.60	46264132	09/08/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	09/07/2023	RSU	Issuer			6666	09/07/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason Smith 9 HA'TA'ASIYA ST RA'ANANA L3 4365007	Ordinary	07/28/2025	7522	143971.08

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for URGN report?

The Form 144 reports a proposed sale of 1,520 ordinary shares valued at $28,697.60, to be executed through Oppenheimer around 09/08/2025.

How were the shares to be sold acquired?

The shares were acquired as RSUs on 09/07/2023, with 6,666 units reported as acquired on that date.

Has the filer sold shares recently?

Yes. The filer reported a sale of 7,522 ordinary shares on 07/28/2025, producing $143,971.08 in gross proceeds.

What broker is handling the proposed sale?

The filing lists Oppenheimer & Co., 85 Broad St., New York, NY 10004 as the broker for the proposed sale.

How large are these sales relative to outstanding shares?

The issuer has 46,264,132 shares outstanding; the proposed sale of 1,520 shares is a very small fraction of that total.